Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=abstract
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=abstract", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=abstract", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=abstract", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=abstract" }, "data": [ { "type": "Grant", "id": "15383", "attributes": { "award_id": "1R01DA059457-01A1", "title": "A Growing Crisis of Novel Injection-Related Wounds and Skin & Soft Tissue Infections among People Who Inject Drugs: A Community-Based, Longitudinal Investigation in North Carolina", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 23652, "first_name": "MELISA RAY", "last_name": "Creamer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-30", "end_date": "2028-08-31", "award_amount": 661013, "principal_investigator": { "id": 31983, "first_name": "Jon Eric", "last_name": "Zibbell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 809, "ror": "", "name": "RESEARCH TRIANGLE INSTITUTE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose a community-based, longitudinal, mixed-methods study to investigate the growing crisis of injection-related wounds and skin and soft tissue infections (IWSSTIs) among people who inject drugs (PWID) in the United States. Lost among the data on skyrocketing overdose deaths is an alarming increase in the prevalence and severity of novel IWSSTIs. IWSSTIs are a leading cause of morbidity for PWID and the most common cause of hospitalizations. More than 100,000 IWSSTIs have occurred annually since 2018. When left untreated, IWSSTIs can become septic, gangrene, and progress to catastrophic infections that require complicated surgeries and long-term medical care. IWSSTIs can stress hospital systems already overburdened with COVID-19, consume limited Medicaid funding, and increase stigma toward PWID. While IWSSTIs have been a concern for PWID for decades, rising incidence of dermal reactions and antinociceptive effects from synthetic drugs and novel psychoactive substances (NPS) represents a new and emerging public health crisis. The Office of National Drug Control Policy recently listed xylazine as an emerging threat and the Centers for Disease Control and Prevention warned of xylazine’s growing involvement in fentanyl overdose deaths. Aim 1: To observe, examine, and typologize IWSSTIs by DSS factors through Consensus-based Clinical Case Reporting Guideline Development (CARE)26-informed case reports, ethnographic interviews, and community-based drug checking among a qualitative sample of 30 PWID (15/site) in western NC; Aim 2: To examine associations between DSS factors and IWSSTI risk among a longitudinal cohort of PWID in NC (N = 450). To achieve these aims, we will recruit PWID from SSPs, homeless encampments, motels, and other places where PWID reside and congregate at the two study sites and surrounding counties (see Facilities). Aim 1 will be accomplished using targeted sampling methods and Aim 2 will be accomplished using respondent-driven sampling (RDS). The study will be led by Principal Investigator Jon Zibbell, a National Institute on Drug Abuse (NIDA)–funded behavioral scientist with many years of experience studying injection drug use and infectious disease risk among PWID. The team also includes William Zule, a NIDA-funded epidemiologist; Arnie Aldridge, a National Institutes of Health–funded statistician; Asher Schranz, a physician and medical expert in injection-related infectious diseases; and Sarah Duhart Clarke, an applied psychologist. Findings from the proposed study will help characterize the etiology and unique features of IWSSTs by DSS factors and quantify xylazine prevalence in the illicit drug supply in western NC. Because growing xylazine contamination and sharp growth in novel IWSSTIs among PWID together comprise an emerging crisis, these data are time sensitive, and the proposed study is poised to make a timely and effective contribution to inform public health response.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8856", "attributes": { "award_id": "1R21OH012201-01", "title": "Moral Injury Among Healthcare Workers on the Frontlines of the COVID-19 Crisis: Developing a Blueprint for Awareness, Prevention, and Mitigation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24486, "first_name": "Maria", "last_name": "Lioce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2023-08-31", "award_amount": 196396, "principal_investigator": { "id": 24672, "first_name": "Natalie J", "last_name": "Purcell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1768, "ror": "", "name": "NORTHERN CALIFORNIA INSTITUTE/RES/EDU", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1768, "ror": "", "name": "NORTHERN CALIFORNIA INSTITUTE/RES/EDU", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose a mixed-methods exploratory study to examine moral injury among healthcare workers who have served on the frontlines during the COVID-19 crisis. We aim to assess the prevalence and impact of moral injury related to the COVID-19 crisis, and to identify key risk and protective factors among healthcare workers stationed in high-risk Veterans Affairs (VA) settings. Then, in partnership with VA stakeholders, we will use study findings to design a pragmatic, testable organizational strategy (a “Blueprint”) for moral injury awareness, mitigation, and prevention in healthcare settings. The study will be carried out in three phases: In PHASE 1 (Months 1-9), we will survey healthcare workers (n=300) in VA emergency rooms, inpatient units, and nursing homes. Surveys will assess moral injury, stress, burnout, depression, work climate, and COVID-19-related exposures. We also will gather VA administrative data on COVID hospitalizations/deaths, care quality, and patient/staff satisfaction. We will analyze collected data to identify moral injury risk and protective factors. In PHASE 2 (Months 9-15), we will conduct qualitative interviews (n=30) with workers to gain a more nuanced understanding of moral injury impacts, risks, and protective factors, as well as desired interventions. In PHASE 3 (Months 15-24), we will develop a Blueprint for Moral Injury Awareness, Prevention, & Mitigation in Healthcare Organizations. We will refine it through focus groups with VA stakeholders. The study is designed to address NIOSH’s goals for the Health Care & Social Assistance [62] NORA (National Occupational Research Agenda) Sector, including the Strategic Goals to: “improve workplace safety to reduce traumatic injuries” [6] and “promote safe and healthy work design and well-being” [7], and the Intermediate Goal to “conduct basic/etiologic research to better understand the burden of non-fatal injuries in healthcare and social assistance and associated risk factors” [6.4.1]. This project addresses these goals by examining the prevalence and impact (burden) of moral injury—a trauma-related mental health injury—among healthcare workers, examining individual and organizational risk/protective factors, and producing a Blueprint to help healthcare organizations reduce moral injuries and promote healthcare workers’ wellbeing. This project aligns with the NIOSH Research to Practice (r2p) initiative by: (a) engaging key stakeholders (partnering VA facilities), (b) addressing questions of concern to them, (c) creating a plan to rapidly translate study findings into a product they can pilot, and (d) refining that product through stakeholder engagement. Study outputs will include the Blueprint for Moral Injury Awareness, Prevention, & Mitigation and scholarly publications. Intermediate outcomes will include: (a) improved understanding of the prevalence and impact of moral injury among healthcare workers, (b) identification of risk and protective factors, and (c) dissemination of promising practices for prevention and mitigation. The end outcome—reduced moral injury prevalence and impact among healthcare workers—will be measured in a future R01 implementation-effectiveness trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6991", "attributes": { "award_id": "3UL1TR002489-03S4", "title": "ICEES+ COVID-19 Open Infrastructure to Democratize and Accelerate Cross-Institutional Clinical Data Sharing and Research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21379, "first_name": "SOJU", "last_name": "Chang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-01", "end_date": "2022-02-28", "award_amount": 412692, "principal_investigator": { "id": 21380, "first_name": "John Bernard", "last_name": "Buse", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21381, "first_name": "NICHOLAS J", "last_name": "SHAHEEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose a novel technical, regulatory, and cultural solution to support research on COVID- 19 and establish the open infrastructure required to respond to the next pandemic: ICEES+ COVID-19. The proposed work will build on the prior work that our team has been engaged with as part of the Biomedical Data Translator program (‘Translator’), funded by the National Center for Advancing Translational Sciences (NCATS), to research and develop the Integrated Clinical and Environmental Exposures Service (ICEES). ICEES represents a unique, disease-agnostic framework and approach to support open sharing of and research on sensitive patient data that have been integrated at the patient and visit level with public exposures data. Importantly, ICEES has been validated in the context of our initial driving use case on asthma. We will extend this effort to instantiate an ICEES+ COVID-19 open infrastructure, focused on patients at UNC Health who have been tested (positive or negative) for COVID-19. The proposed work will leverage not only our prior Translator work, but also new work that our team has been engaged with as part of the NCATS Center for Data to Health (CD2H) National Covid Cohort Collaborative (N3C). Indeed, the North Carolina Translational and Clinical Sciences Institute (home to UNC’s CTSA) was selected by CD2H leadership to lead the technical implementation of significant portions of the N3C initiative. We will adopt the N3C COVID-19 consensus phenotype for the proposed work and extend the captured data fields to include relevant data fields that were intentionally excluded by the N3C collaborative in their effort to promote uniformity and participation, but are available via our local clinical data warehouse, such as temperature, oxygen saturation, isolation flags, and other potentially relevant clinical features (e.g., blood type). We also have partnered with investigators affiliated with the Environmental Polymorphisms Registry at the National Institute for Environmental Health Sciences and will be exposing data on their registry participants. Our overall aims are to develop and deploy ICEES+ COVID-19, apply ICEES+ COVID-19 to support research on COVID-19, and promote widespread use of ICEES+ COVID-19, largely through our engagement with the Translator program, CD2H N3C, and other large-scale collaboratives. A key aspect of the proposed work is that ICEES+COVID-19 will be open source, which will allow other institutions to rapidly adopt our approach and expose their data for open analysis of COVID-19 data by a much larger community. Collectively, the proposed work will catalyze efforts to respond to the COVID-19 pandemic and position society to be better prepared for the next one.", "keywords": [ "Adopted", "Adoption", "Asthma", "Automobile Driving", "Biological", "Blood", "COVID-19", "COVID-19 pandemic", "Center for Translational Science Activities", "Clinical", "Clinical Data", "Clinical Sciences", "Collaborations", "Communities", "Consensus", "Critical Care", "Data", "Data Pooling", "Disease", "Documentation", "Environmental Exposure", "Exposure to", "Foundations", "Funding", "Genes", "Genetic Determinism", "Genetic Polymorphism", "Health", "Home environment", "Infection", "Infrastructure", "Institutes", "Institution", "Intervention", "Knowledge", "Lead", "Leadership", "Link", "Lung diseases", "National Heart Lung and Blood Institute", "National Institute of Environmental Health Sciences", "North Carolina", "Obesity", "Oxygen", "Participant", "Pathway interactions", "Patients", "Pharmaceutical Preparations", "Phenotype", "Positioning Attribute", "Publications", "Publishing", "Readiness", "Registries", "Research", "Research Personnel", "Research Support", "Respiration", "Risk", "Science", "Services", "Severity of illness", "Societies", "Speed", "System", "Temperature", "Testing", "Translational Research", "Ventilator", "Viral", "Visit", "Work", "base", "catalyst", "clinical data warehouse", "clinical infrastructure", "clinically relevant", "cohort", "comorbidity", "coronavirus disease", "data sharing", "design", "expectation", "experience", "fight against", "genetic variant", "high risk population", "insight", "knowledge graph", "novel", "open data", "open source", "pandemic disease", "patient subsets", "programs", "research study", "response", "tool", "web site" ], "approved": true } }, { "type": "Grant", "id": "5124", "attributes": { "award_id": "NNX10AR42G", "title": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-01", "end_date": "2012-12-31", "award_amount": 0, "principal_investigator": { "id": 18257, "first_name": "DAVID", "last_name": "BUOTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1407, "ror": "", "name": "REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (6406)", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7336", "attributes": { "award_id": "3U19AI142733-02S1", "title": "Modulation of lung immunity by CoronaVirus", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6018, "first_name": "Chao", "last_name": "Jiang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-04-08", "end_date": "2023-02-28", "award_amount": 518190, "principal_investigator": { "id": 7178, "first_name": "Anna Karolina KAROLINA", "last_name": "Palucka", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 873, "ror": "https://ror.org/021sy4w91", "name": "Jackson Laboratory", "address": "", "city": "", "state": "ME", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 873, "ror": "https://ror.org/021sy4w91", "name": "Jackson Laboratory", "address": "", "city": "", "state": "ME", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose a U19 Cooperative Center on Human Immunology at The Jackson Laboratory (JAX CCHI) to elucidate the innate immune networks that shape adaptive immune responses to respiratory viral infections in the human lung. Epithelial barriers lie at the interface between host and environment, where they sense invading pathogen. Dendritic cells (DCs) present pathogen-derived antigens to T and B cells to induce immune responses. However, the impact of the human lung tissue environment on DC and other cells, such as the newly identified innate lymphoid cell (ILC) family, as well as bacteria-reactive MAIT cells, is not completely understood. An understudied environmental factor is the lung microbiome. Microbiota are known to critically modulate the function of immune cells, particularly at mucosal surfaces, but how this occurs in the lung is not fully addressed. The JAX CCHI seeks to address these critical questions using a multi-disciplinary experimental approach that will integrate immunology with epithelial cell biology along with genomic, cellular, functional and microbiome parameters identified in human lung tissues. Our overarching hypothesis is that the quality and magnitude of mucosal T cell responses to respiratory viral infections are determined by the crosstalk between microbiota, epithelial cells and leukocytes. To address this hypothesis, we structured the JAX CCHI around two integrated research projects focused on basic immunological mechanisms of lung antiviral immunity; a technology development project that will create sophisticated cellular models leveraging 3D bioprinting, gene editing tools and microbiome-immune assays to support project objectives; a sample core for storage and distribution of human tissues; and a microbiome core for specialized microbiome profiling, cultivation, and computational analysis. Our Center will bring together clinicians with experts in lung immunology, the microbiome, bioengineering, genomics and computational biology to achieve our goals and maximize the potential of this research. An administrative core will provide coordination, communication and oversight for the program. The goals of this CCHI are to: 1) Understand how the networks of epithelial cells and immune cells in the human lung regulate innate and adaptive immunity to respiratory viruses; 2) Define how inflammation driven by the microbiome dictates the steady state of tissue, i.e., immune set-point; 3) Determine if and how this immune set-point is altered in two pulmonary diseases, childhood asthma and adult lung cancer which have a major impact on public health; and 4) Develop innovative technologies to", "keywords": [ "2019-nCoV", "3-Dimensional", "ATAC-seq", "Address", "Adult", "Air", "Alternative Splicing", "Alveolar", "Antibodies", "Antigens", "B-Lymphocytes", "Bacteria", "Biological", "Biomedical Engineering", "COVID-19", "CRISPR/Cas technology", "Cell model", "Cells", "Cellular Tropism", "Cellular biology", "Cessation of life", "Childhood Asthma", "Chiroptera", "Clustered Regularly Interspaced Short Palindromic Repeats", "Collaborations", "Communication", "Computational Biology", "Computer Analysis", "Coronavirus", "Coronavirus Infections", "Country", "Dendritic Cells", "Development", "Disease", "Disease Outbreaks", "Disease Outcome", "Encephalitis", "Environment", "Environmental Risk Factor", "Epidemic", "Epithelial", "Epithelial Cells", "Epithelium", "Family", "Family member", "Generations", "Genes", "Genetic Transcription", "Genomics", "Goals", "Harvest", "Human", "Immune", "Immune System Diseases", "Immune response", "Immunity", "Immunologics", "Immunology", "Immunology procedure", "In Vitro", "Infection", "Inflammation", "Influenza", "Invaded", "Investigation", "Leukocytes", "Liquid substance", "Lung", "Lung diseases", "Lymphoid Cell", "Malignant neoplasm of lung", "Molecular Analysis", "Molecular Target", "Mucous Membrane", "Mus", "Names", "Natural Immunity", "Organoids", "Parents", "Pathway interactions", "Pediatric Hospitals", "Phylogenetic Analysis", "Pneumonia", "Proteins", "Public Health", "Research", "Research Project Grants", "Resources", "Respiratory System", "SARS coronavirus", "Sampling", "Severe Acute Respiratory Syndrome", "Shapes", "Source", "Structure", "Structure of parenchyma of lung", "Surface", "Syndrome", "System", "T cell response", "T-Lymphocyte", "Technology", "Testing", "The Jackson Laboratory", "Time", "Tissues", "Transgenic Mice", "Validation", "Viral", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "Work", "World Health Organization", "adaptive immune response", "adaptive immunity", "antiviral immunity", "base", "bioprinting", "cellular targeting", "flu", "human disease", "human tissue", "immune function", "immunological status", "in vivo", "influenzavirus", "innovative technologies", "lung microbiome", "microbial", "microbiome", "microbiota", "mouse model", "multidisciplinary", "novel", "novel coronavirus", "novel therapeutics", "pandemic disease", "pathogen", "preference", "preservation", "programs", "receptor", "respiratory", "respiratory virus", "re" ], "approved": true } }, { "type": "Grant", "id": "10606", "attributes": { "award_id": "1R42ES034684-01", "title": "Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 26260, "first_name": "Lingamanaidu V.", "last_name": "Ravichandran", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-13", "end_date": "2023-08-31", "award_amount": 259573, "principal_investigator": { "id": 26648, "first_name": "ALEXANDER V", "last_name": "MAMISHEV", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1951, "ror": "", "name": "SPECTREE INC.", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose developing and validating a novel platform technology that combines the collection and chemical analysis of ultrafine particles using an in-situ multispectral technique. The sample, collected directly onto the analysis substrate, is analyzed via excitation-emission matrix (EEM) spectroscopy. This approach will be validated against laboratory combustion-generated aerosols, such as diesel exhaust, wood smoke, tobacco smoke, and against a mixture of environmental pollutants. Within the respiratory tract, particle size determines the region of deposition and tissue uptake; the chemistry of the particle also affects solubility and determines the potential for biochemical reaction with tissues and cells. There is a growing awareness that exposure scenarios are very complex, consisting of time-varying concentrations and chemical composition over a broad range of particle sizes. Long-term exposure to air pollution has also been linked to increased mortality rates for infectious diseases, including COVID-19. The proposed research addresses the need for improved personal exposure assessment and characterization of ultrafine particles in the environment. Low-cost, miniaturized exposure monitoring devices can shed insight into the relationships between exposure to pollutants and health impact. Source apportioned measurements of PM concentration with high temporal and spatial resolution can facilitate the implementation of optimal air pollution mitigation strategies. The anticipated outcome of this project is the development of a miniaturized spectroscopic sensor that provides an analysis of the chemical composition of combustion-generated ultrafine particles, which both reflects the particle sources and determines their toxic potential. The machine-learning algorithms will enable the deconvolution of the complex spectra and identification of the PM source from the EEM analysis. The broader applications of the technology are environmental and regulatory monitoring, personal exposure assessment for the consumer market, and epidemiological studies.", "keywords": [ "Address", "Aerosols", "Affect", "Air", "Air Pollution", "Automation", "Awareness", "Biochemical Reaction", "COVID-19", "Carbon", "Cells", "Chemicals", "Chemistry", "Childhood", "Clinical", "Clinical Research", "Collaborations", "Collection", "Communicable Diseases", "Complex", "Cost Analysis", "Cost Savings", "Data", "Deposition", "Development", "Diesel Exhaust", "Electrostatics", "Engineering", "Environment", "Environmental Pollutants", "Environmental and Occupational Exposure", "Evaluation", "Evidence based intervention", "Exposure to", "Health", "In Situ", "Individual", "Inhalation", "Institutional Review Boards", "Intervention", "Laboratories", "Libraries", "Link", "Machine Learning", "Measurement", "Medical", "Methods", "Miniaturization", "Monitor", "Optics", "Outcome", "Participant", "Particle Size", "Particulate Matter", "Performance", "Phase", "Preparation", "Research", "Research Design", "Resolution", "Respiratory System", "Sampling", "Signal Transduction", "Solid", "Solubility", "Solvents", "Source", "Specificity", "Spectrum Analysis", "Techniques", "Technology", "Testing", "Time", "Tissues", "Tobacco smoke", "Ultrafine", "absorption", "air pollution control", "base", "commercialization", "cost", "cost effective", "design", "detection platform", "environmental agent", "epidemiology study", "implementation facilitation", "improved", "insight", "instrumentation", "machine learning algorithm", "miniaturize", "monitoring device", "mortality", "nanomaterials", "novel", "particle", "particle counter", "personal exposure monitor", "pollutant", "public health research", "pulmonary function", "relating to nervous system", "sensor", "solvent extraction", "tool", "ultrafine particle", "uptake", "wood smoke" ], "approved": true } }, { "type": "Grant", "id": "10235", "attributes": { "award_id": "3U01DA053941-02S1", "title": "Supplement for MINI point-of-use device", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22394, "first_name": "Tamara", "last_name": "Slipchenko", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2022-12-31", "award_amount": 170998, "principal_investigator": { "id": 23948, "first_name": "Christopher Edward", "last_name": "Mason", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1514, "ror": "", "name": "UNIVERSITY OF MIAMI CORAL GABLES", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23949, "first_name": "Stephan C", "last_name": "Schürer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 23950, "first_name": "Helena", "last_name": "Solo-Gabriele", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1514, "ror": "", "name": "UNIVERSITY OF MIAMI CORAL GABLES", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose portable, proven, point of care/surveillance devices for use in SARS-CoV-2 testing that expands upon the TINY (Tiny Isothermal Nucleic acid quantification sYstem) , which is called the MINI. These devices leverage LAMP (loop mediated isothermal amplification) technology developed by the Mason Lab in collaboration with technological developments from the Erickson lab to test up to 96 samples in real time. These devices can operate in areas without existing medical infrastructure with portability and high throughput, filling an existing gap in the current SARS-CoV-2 testing infrastructure. We also envision these devices as filling a necessary gap in COVID-19 surveillance, leveraging pilot studies in detecting SARS-CoV-2 and other viruses in sewage to monitor the evolution of the pandemic in the coming years and building an infrastructure to better monitor and predict future viral outbreaks. A 96 well version of our existing TINY detection device, called the MINI, will be deployed at large scale to develop surveillance and point of care testing for SARS-CoV-2 in wastewater, saliva, and other samples. This technology is accompanied by an easy to use software package for exporting and preserving results that can be installed on any computer. This technology is able to screen the most prevalent circulating COVID-19 variants by targeting the viral envelope gene (E) and RNAse P (RP) gene. These methods can help with the current COVID-19 outbreak and aid in future risk management and pathogen mapping.", "keywords": [ "2019-nCoV", "Area", "COVID-19", "COVID-19 detection", "COVID-19 outbreak", "COVID-19 surveillance", "COVID-19 testing", "Collaborations", "Computer software", "Computers", "Development", "Devices", "Disease Outbreaks", "Evolution", "Future", "Genes", "Infrastructure", "Mediating", "Medical", "Methods", "Monitor", "Nucleic Acids", "Pilot Projects", "Process", "RNase P", "Risk Management", "SARS-CoV-2 variant", "Saliva", "Sampling", "Sewage", "System", "Technology", "Testing", "Time", "Viral", "Viral Envelope Gene", "Virus", "detection platform", "isothermal amplification", "pandemic disease", "pathogen", "point of care", "point of care testing", "portability", "preservation", "tool" ], "approved": true } }, { "type": "Grant", "id": "6044", "attributes": { "award_id": "5P20GM125507-04", "title": "COBRE Center on Opioids and Overdose", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20619, "first_name": "Crina", "last_name": "Frincu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-09-01", "end_date": "2023-08-31", "award_amount": 2409022, "principal_investigator": { "id": 20620, "first_name": "JOSIAH D", "last_name": "RICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose to build and sustain the Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose at Rhode Island Hospital and affiliated research institutions. The motivation for this effort lies in the tremendous need for greater scientific understanding of the mechanisms underpinning vulnerability to opioid use disorder and a need for more effective interventions to treat and prevent opioid misuse and overdose. We will approach these challenges through ongoing, cooperative partnership among senior scientists and early career investigators across several complementary disciplines. We propose a unique and innovative mentoring strategy that, in addition to primary project advising, will provide junior faculty members with specialized mentorship and services that empowers investigators to influence policy and practice through their research. Moreover, we will build four interdisciplinary cores that will provide infrastructure, consultation, and additional support services to ensure the successful career development of our Project Leaders. The long-term goal of the Center is to develop and sustain a critical mass of investigators specializing in opioids and overdose that benefits affected populations and enhances the competitiveness of affiliated investigators. The objective of this proposal is to establish and build the COBRE Center and to support the research activities of junior Project Leaders to ensure their transition to R01-funded scientists. There are two Specific Aims—one related to the establishment of a new disease-specific research center, and one encompassing four Research Projects that are linked by the themes of opioids and overdose. Aim 1: Establish the cores needed to develop and sustain a thematic multidisciplinary center of research excellence on opioids and overdose. Four cores will be created to achieve this aim: an Administrative Core, a Data and Research Methods (DRM) Core, a Translational and Transformative (T2) Core, and a Special Populations (SP) Core. Aim 2: Support the selection, mentorship, and career development of early career faculty Project Leaders. The four initial research projects are: Project 1: (Beaudoin) “Informed opioid prescribing for acute musculoskeletal pain after motor vehicle collision: A support tool for assessing risks and benefits of analgesic medications before prescribing (STAAMP),” Project 2: (Claborn) “Prevention of Opioid Overdose following Incarceration: Leveraging Mobile Health Technology,” Project 3: (Becker) “Contingency Management in Combination with MAT for Opioid Use Disorders,” and Project 4: (Czynski) “Neonatal Abstinence Syndrome (NAS): Fetus to First Years.” The proposed center will bring together an interdisciplinary group of accomplished senior scientists, promising junior investigators, and distinguished advisors and collaborators to work closely together to establish a center of excellence in an area of clinical research that is of critical public health importance.", "keywords": [ "Accidental Injury", "Acute", "Address", "Affect", "Analgesics", "Area", "Benefits and Risks", "Caring", "Centers for Disease Control and Prevention (U.S.)", "Centers of Research Excellence", "Cessation of life", "Clinical Research", "Collaborations", "Consultations", "Country", "Data", "Data Management Resources", "Discipline", "Disease", "Doctor of Philosophy", "Education and Outreach", "Ensure", "Epidemic", "Ethics", "Faculty", "Fentanyl", "Fetus", "Funding", "Goals", "Health Technology", "Heroin", "Hospitals", "Imprisonment", "Individual", "Infrastructure", "Institution", "Joints", "Knowledge", "Leadership", "Link", "Mentors", "Mentorship", "Methodology", "Motivation", "Musculoskeletal Pain", "Neonatal Abstinence Syndrome", "Opiate Addiction", "Opioid", "Overdose", "Pattern", "Pharmaceutical Preparations", "Policies", "Population", "Prevention", "Prevention approach", "Public Health", "Research", "Research Activity", "Research Design", "Research Methodology", "Research Personnel", "Research Project Grants", "Research Support", "Resources", "Rhode Island", "Scientist", "Senior Scientist", "Services", "Special Population", "Strategic Planning", "Surgeon", "Translational Research", "United States", "United States National Institutes of Health", "Vehicle crash", "Vulnerable Populations", "Work", "career", "career development", "cohort", "contingency management", "data visualization", "early-career faculty", "effective intervention", "high risk population", "implementation science", "innovation", "mHealth", "member", "multidisciplinary", "opioid misuse", "opioid overdose", "opioid use disorder", "organizational structure", "prescription opioid", "prevent", "programs", "recruit", "support tools" ], "approved": true } }, { "type": "Grant", "id": "8095", "attributes": { "award_id": "75N92021P00053-0-0-1", "title": "RADX TECH PROJECT - WORK PACKAGE 1 SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-04", "end_date": "2022-02-03", "award_amount": 250000, "principal_investigator": { "id": 23979, "first_name": "PING", "last_name": "WANG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose to detect acute SARS-CoV-2 infections using a sample-to-answer portable device detecting very low concentrations of viral antigens using our patented microbubbling digital assay technology.", "keywords": [ "Acute", "Biological Assay", "Devices", "Legal patent", "RADx Tech", "SARS-CoV-2 infection", "Sampling", "Technology", "Viral Antigens", "Work", "digital", "portability" ], "approved": true } }, { "type": "Grant", "id": "8037", "attributes": { "award_id": "75N92021P00050-0-0-1", "title": "RADX-TECH- SUPPORT SERVICES NEEDED FOR WORK PACKAGE 1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-01-19", "end_date": "2022-01-18", "award_amount": 250000, "principal_investigator": { "id": 23932, "first_name": "ANDREA", "last_name": "PAIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1663, "ror": "", "name": "NOVEL MICRODEVICES, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1663, "ror": "", "name": "NOVEL MICRODEVICES, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose to develop a rapid (under 20-minute), point-of-care (PoC) Reverse Transcriptase Loop-mediated Amplification (RT-LAMP) test for the detection of SARS COV-2 virus from human nasal and oral swab and saliva samples. Our SARS-CoV2 RT-LAMP assay will be implemented on our Novel Dx system which comprises an easy-to-use, affordable, ultraportable instrument that performs a fully-automated nucleic acid amplification test (NAAT) on a self-contained, disposable, test-specific cartridge. Development of this assay will enable SARS CoV-2 testing to be performed in lab-free healthcare settings such as CLIA-waived clinics and physician offices as well as in non-healthcare settings including offices, retail centers, airports and homes. In addition to the development and implementation of a SARS COV-2 RT-LAMP assay on our NovelDx instrument/cartridge system for point-of-care and lab-free settings, the developed LAMP assay will itself be made available for implementation in labs as a mid-to-high throughput SARS-CoV-2 testing solution. Doing so will greatly increase U.S. capacity for and accessibility to SARS-CoV-2 testing by enabling rapid, highly sensitive and specific isothermal molecular tests to be performed in basic laboratories not otherwise equipped for typical PCR thermocycling-based nucleic acid analyses. Analytical and Clinical Studies on the Novel Dx SARS-CoV-2 test will be performed as per the FDA Emergency Use Authorization (EUA) Guidance, to obtain use authorization. Subsequently we aim to develop a multiplex Flu-A/Flu-B/SARS-CoV-2 assay to detect and differentiate between Influenza and COVID-19 infections. We plan to submit a dual 510(k) and CLIA waiver application for marketing the Novel Dx Flu-A/Flu-B/SARS-CoV-2 test to US healthcare facilities.", "keywords": [ "2019-nCoV", "Authorization documentation", "Biological Assay", "COVID-19 assay", "COVID-19 detection", "COVID-19 test", "COVID-19 testing", "Clinic", "Clinical Research", "Development", "FDA Emergency Use Authorization", "Health care facility", "Home", "Human", "Laboratories", "Marketing", "Mediating", "Molecular", "Nose", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Oral", "Physicians&apos", "Offices", "Point-of-Care Systems", "RADx Tech", "RNA-Directed DNA Polymerase", "SARS-CoV-2 infection", "Services", "Swab", "System", "Testing", "Virus", "Work", "assay development", "base", "detection test", "flu", "health care settings", "influenza infection", "instrument", "novel", "point of care", "saliva sample", "waiver" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1424, "count": 14236 } } }